- Gatsbie
- Investor lists
- Biotech & Life Sciences
- Biotech and Healthcare
Biotech and Healthcare investors
363 funds · Updated
Gatsbie lists 363 Biotech and Healthcare investors (as of 2026-11-18).
Each one names both biotech & life sciences and healthcare & medtech in its investment focus.
Most are based in United States (218), United Kingdom (33) and Germany (13); the most common stages are Seed (311), Series A (295) and Pre-Seed (242); the most common kinds of capital are Venture equity (338), Growth equity (113) and Buyout (46).
Which investors back Biotech and Healthcare startups?
Gatsbie lists 363 Biotech and Healthcare investors (as of 2026-11-18). Most are in United States (218), United Kingdom (33) and Germany (13). They include Amoon Fund (Ra'anana), Development Partners International (London), Claret Capital Partners (London), Redalpine Venture Partners AG (Zürich), Andreessen Horowitz (Menlo Park) and DCVC (San Francisco). Most deals on record in the last 24 months: Amoon Fund (7 deals), Development Partners International (3 deals) and Claret Capital Partners (2 deals).
Which family offices invest in Biotech and Healthcare?
23 of the 363 Biotech and Healthcare investors on Gatsbie are family offices, including Sopris Venture Capital, Alychlo, INTERGROUP PARTNERS AG, TARSADIA INVESTMENTS and BROADVIEW VENTURES.
Upload your deck to see which of these fit your startup, with a written reason for each.
20 of 363 funds
Most active first: deals in the last 24 months, then portfolio companies on record.
| # | Fund | HQ | Stages | Partner emails |
|---|---|---|---|---|
| 1 | Amoon Fund | Ra'anana | Seed–Series C+ | 15 |
| 2 | Development Partners International | London | Seed–Series C+ | 10 |
| 3 | Claret Capital Partners | London | Pre-Seed–Series A, Growth | 15 |
| 4 | Redalpine Venture Partners AG | Zürich | Pre-Seed–Series A, Series C+ | 12 |
| 5 | Andreessen Horowitz | Menlo Park | Seed–Series C+ | 38 |
| 6 | DCVC | San Francisco | Pre-Seed–Series B | 11 |
| 7 | HOF Capital | New York | Pre-Seed–Series B | 16 |
| 8 | 8VC | San Francisco | Seed–Series C+ | 19 |
| 9 | SV Health Investors | Boston | Pre-Seed–Series B | 22 |
| 10 | Aisling Capital | New York | Seed–Series C+ | 6 |
| 11 | F-Prime Capital | Cambridge | Pre-Seed–Series B | 32 |
| 12 | Innovation Endeavors | Palo Alto | Pre-Seed–Series B | 9 |
| 13 | Air Street Capital | London | Pre-Seed–Series B | 1 |
| 14 | BlueYard | Berlin | Pre-Seed–Series A, Series C+ | 12 |
| 15 | General Catalyst | Prague | Pre-Seed–Series B | 10 |
| 16 | Avalon Ventures | La Jolla | Pre-Seed–Series B | 6 |
| 17 | Eight Roads Ventures | London | Seed–Series C+ | 11 |
| 18 | Foresite Capital | San Francisco | Pre-Seed–Series B | 12 |
| 19 | Metavallon Venture Capital | – | Pre-Seed, Seed | 8 |
| 20 | Andera Partners | Paris | Seed–Series C+ | 71 |
See more Biotech and Healthcare investors in Investor Discovery
Other sector pairs
Biotech and Healthcare investors elsewhere
Biotech & Life Sciences investors by school
- Harvard University 186
- Stanford University 139
- University of Pennsylvania 124
- Columbia University 83
- University of California, Berkeley 69
- University of Oxford 69
- University of Cambridge 67
- Massachusetts Institute of Technology (MIT) 59
- Northwestern University 57
- London School of Economics (LSE) 51
- Duke University 49
- University of Chicago 49
- Yale University 47
- New York University 46
- INSEAD 42
- University of Michigan 38
Counted by where each fund is headquartered, from public sources, as of 2026-11-18. Only funds naming both sectors are listed.
